» Articles » PMID: 31677604

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

Overview
Journal Iran Biomed J
Date 2019 Nov 4
PMID 31677604
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recently, modification of T cells with chimeric antigen receptor (CAR) has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a single-chain variable domain fragment (scFv). Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell clearance. Nanobody is a specific antigen-binding fragment derived from camelid that has great homology to human VH and low immunogenic potential. Therefore, in this study, nanobody was employed instead of scFv in CAR construct.

Methods: In this study, a CAR was constructed based on a nanobody against PSMA (NBPII-CAR). At first, Jurkat cells were electroporated with NBPII-CAR, and then flow cytometry was performed for NBPII-CAR expression. For functional analysis, CAR T cells were co-cultured with prostate cancer cells and analyzed for IL-2 secretion, CD25 expression, and cell proliferation.

Results: Flow cytometry results confirmed the expression of NBPII-CAR on the transfected Jurkat cells. Our data showed the specificity of engineered Jurkat cells against prostate cancer cells by not only increasing the IL-2 cytokine (about 370 pg/ml) but also expressing the T-cell activation marker CD25 (about 30%). In addition, proliferation of engineered Jurkat cells increased nearly 60% when co-cultured with LNCaP (PSMA+), as compared with DU145 (PSMA-).

Conclusion: Here, we describe the ability of nanobody-based CAR to recognize PSMA that leads to the activation of Jurkat cells. This construct might be used as a promising candidate for clinical applications in prostate cancer therapy.

Citing Articles

Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs.

Guo S, Xi X Biomark Res. 2025; 13(1):41.

PMID: 40069884 PMC: 11899093. DOI: 10.1186/s40364-025-00755-5.


Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.

Jahan F, Koski J, Schenkwein D, Yla-Herttuala S, Goos H, Huuskonen S Front Mol Med. 2024; 3:1070384.

PMID: 39086686 PMC: 11285682. DOI: 10.3389/fmmed.2023.1070384.


Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.

Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Abdoli S, Sayadi M BMC Biotechnol. 2024; 24(1):1.

PMID: 38178096 PMC: 10768260. DOI: 10.1186/s12896-023-00827-0.


Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.

He M, Cao Y, Chi C, Zhao J, Chong E, Chin K Front Immunol. 2023; 14:1265751.

PMID: 37795091 PMC: 10545965. DOI: 10.3389/fimmu.2023.1265751.


Chimeric antigen receptor-natural killer cells: a promising sword against insidious tumor cells.

Hojjatipour T, Sharifzadeh Z, Maali A, Azad M Hum Cell. 2023; 36(6):1843-1864.

PMID: 37477869 DOI: 10.1007/s13577-023-00948-w.


References
1.
Harding F, Stickler M, Razo J, DuBridge R . The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PMC: 2881252. DOI: 10.4161/mabs.2.3.11641. View

2.
Harmsen M, De Haard H . Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; 77(1):13-22. PMC: 2039825. DOI: 10.1007/s00253-007-1142-2. View

3.
HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

4.
Maus M, Haas A, Beatty G, Albelda S, Levine B, Liu X . T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2014; 1(1):26-31. PMC: 3888798. DOI: 10.1158/2326-6066.CIR-13-0006. View

5.
De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K . Nanobody Based Dual Specific CARs. Int J Mol Sci. 2018; 19(2). PMC: 5855625. DOI: 10.3390/ijms19020403. View